CXCR2 and breast cancer: In human BC PDX, the use of a specific antibody against IL-8 receptor, CXCR-1, or an inhibitory molecule against to CXCR-1 and CXCR-2, repertaxin, favored the eradication of CSC pool, thus impeding tumor progression.